Abstract:
A wireless operating room communication system provides wireless transmission of video signals from a wireless camera or a wireless transmitter unit to a portable wireless display unit. A wireless multiple device control unit is in wireless communication with the transmitter unit, the display unit, and a plurality of surgical devices disposed within the operating room. Each of the surgical devices has a video receiver to obtain a video signal to synchronize the devices and units. The video transmitter unit has a video transmitter and the other units or devices have a non-video transmitter. The arrangement enables transmission of device control signals on the same channel as the video signal. In response to changes in bandwidth, the video transmitter unit reduces the video signal to enable transmission thereof to the video display unit, while maintaining robustness of the control signals.
Abstract:
PROBLEM TO BE SOLVED: To provide a sustained release formulation that contains a crystal of biological agent, polymer gel, and particle suspension.SOLUTION: This invention is directed to the sustained release formulations of a biological agent that enables sustained bioavailability. A bone morphogenetic protein can be pointed out as a desirable biological agent. The diseases expected to be improved and/treated by this formulation include a skeletal tissue disease (for instance, degenerative joint disease and other osteochondral disease, if not limited thereto). This formulation is particularly suitable for the treatment of a tissue site where there is a minimal or no vaascular formation (for instance, intraarticular, interjoint, or meniscal site, if not limited thereto).
Abstract:
PROBLEM TO BE SOLVED: To provide improved osteogenic devices and methods of use thereof for repairing bone defects, cartilage defects, and/or osteochondral defects.SOLUTION: There are disclosed the improved osteogenic devices and methods of use thereof for repair of bone and cartilage defects. The devices and methods promote accelerated formation of repair tissue with enhanced stability using less osteogenic protein than devices in the art. Defects susceptible to repair include, but are not limited to: critical size defects, non-critical size defects, non-union fractures, fractures, osteochondral defects, subchondral defects, and defects resulting from degenerative diseases such as osteochondritis dessicans.
Abstract:
The present invention is directed to methods and compositions for systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-beta superfamily. According to the invention, an exemplary bioactive agent is BMP-7 The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the site of intravascular delivery of the bioactive agent.
Abstract:
PROBLEM TO BE SOLVED: To provide drugs for promoting the survival or growth, or inhibiting the death or degeneration, of mammalian cells (particularly neural cells).SOLUTION: A synergistic effect of OP/BMP morphogen combined with GDNF/NGF neurotrophic factors to promote the survival or growth, or inhibit the death or degeneration of mammalian cells, particularly neural cells, which express OP/BMP-activated serine/threonine kinase receptors and GDNF/NGF-activated tyrosine kinase receptors is disclosed. Also new methods for in vivo and in vitro treatment of such cells, including in vivo treatments for mammals afflicted with, or at imminent risk of, damage or injury to, such cells, as well as new pharmaceutical preparations for such in vivo and in vitro treatments are disclosed.